Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MERUS LABS INTERNATIONAL INC T.MSL

"Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products."


TSX:MSL - Post by User

Comment by mjh9413on Apr 16, 2015 1:00am
168 Views
Post# 23635032

RE:RE:RE:Bought Deal--something in the water today

RE:RE:RE:Bought Deal--something in the water todayMaybe TD is one of the Lenders of the Sintrom deal and that's why they are here. Must say I did not realise how much they paid on a NET sales basis for Sintrom. Appears to be at least 4 1/2 times annual NET sales as opposed to respective 2 1/2 times GROSS.
Be interesting what they do with the proceeds as they seems to be in position to cover current loan amounts due (at $4MM per qtr) +mthly interest at prime+300bp.
I always feel where there is  relatively high proportion of interest added back in to EBITDA  and adjEBITDA a coy distorts these EBITDA  amounts upwards, and thus favorably impacts the related EBITDA to sp ratios. Loan interest is a real cash cost of doing business and I prefer to take it out. However doing this the sp multiple is still only about 11,quite  low for what we trust will be a high frowth rate coy.
GL
ps this one does not have the consistent high daily volumes or the immense hype for the likes of PHM and so the brokers have less control over its price action, hence the relatively poor price performance both before and after the Bought deal announcement.
<< Previous
Bullboard Posts
Next >>